Abstracts tagged "Mortality"

Abstract Number: 1156 • ACR Convergence 2023
Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong
Iris Tang¹, Ho So², Teresa li³, Vivian Tang⁴, Chi Ho⁵ and Roy Ho⁶, ¹Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Queen Mary Hospital, Hong Kong, Hong Kong, ⁴North District Hospital, Hong Kong, Hong Kong, ⁵Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁶Queen Elizabeth Hospital, Hong Kong, Hong Kong
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous autoimmune diseases with cutaneous, musculoskeletal, and systemic involvements. The Hong Kong Myositis Registry (MyoHK) was…
Abstract Number: 1541 • ACR Convergence 2023
Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA
Gatr-alnada Gheriani¹ and Petar Lenert², ¹University of Iowa Hospital and Clinics, Tiffin, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: The aim of this study was to analyze the incidence of nervous system manifestations in a cohort of patients with Microscopic Polyangiitis (MPA) and…
Abstract Number: 2122 • ACR Convergence 2023
Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study
Cristina Corrales Selaya¹, Nuria Vegas Revenga², Jose Antonio Parra³, Virginia Portilla⁴, Ricardo Blanco⁵, Miguel A Gonzalez-Gay⁶, Ivan Ferraz Amaro⁷ and Alfonso Corrales⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Galdakao- Usansolo, Galdakao, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: The risk of mortality is increased in patients with RA compared to the general population. Different non-invasive surrogate markers of atherosclerosis have been implemented…
Abstract Number: 0618 • ACR Convergence 2023
Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis
liubov Petelytska¹, Arthiha Velauthapillai², Lorenzo Tofani³, Patricia Carreira⁴, Giovanna Cuomo⁵, Eric Hachulla⁶, Ivan Castellvi⁷, Radim Becvar⁸, Alexandra Balbir-Gurman⁹, Paolo Airò¹⁰, Irena Litinsky¹¹, Lesley Ann Saketkoo¹², Madelon Vonk¹³, Jeska de Vries-Bouwstra¹⁴, Anna Maria Hoffmann-Vold¹⁵, marco Matucci Cerinic¹⁶, Oliver Distler¹⁷ and Cosimo Bruni¹⁷, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ⁶University of Lille, Lille, France, ⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁸Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ¹¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹²University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Leiden University Medical Center, Leiden, Netherlands, ¹⁵Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ¹⁶Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Although 50% of patients with systemic sclerosis (SSc) present with interstitial lung disease (ILD) at baseline, new onset of ILD can also occur later…
Abstract Number: 1163 • ACR Convergence 2023
Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort
Sai Koyoda¹, Dawn Wahezi², Xianhong Xie³, Anand Kumthekar⁴, Clement Tagoe³ and Bibi Ayesha⁵, ¹Essen Medical Center, Rahway, NJ, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Bronx, NY
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
Abstract Number: 1542 • ACR Convergence 2023
The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study
Zachary Wallace¹, Xiaoqing Fu², Shruthi Srivatsan², Zachary Williams², Claire Cook², Jennifer Hanberg², John Stone³, Hyon K. Choi⁴ and Yuqing Zhang⁵, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…
Abstract Number: 2127 • ACR Convergence 2023
Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer
Maya Swaminathan¹, Sarah Holt², John Gore², Yaw Nyame², Jonathan Wright², George Schade², Ami Shah³, Jeffrey Sparks⁴, Una Makris⁵, Petros Grivas⁶, Maria Suarez-Almazor⁷, Sarah Psutka² and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Department of Urology, University of Washington, Seattle, WA, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶Division of Medical Oncology, Dept. of Medicine, UW; Clinical Research Division; Fred Hutchinson Cancer Center, Seattle, WA, ⁷MD Anderson Cancer Center, Houston, TX, ⁸University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have…
Abstract Number: 0644 • ACR Convergence 2023
Prediction of Stable SSc-ILD Depends on Definition of ILD Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Carina Mihai⁶, Oyvind Midtvedt¹, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
Abstract Number: 1166 • ACR Convergence 2023
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Emily He¹ and Vaneet Sandhu², ¹Loma Linda University Health, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA
Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…
Abstract Number: 1622 • ACR Convergence 2023
Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality
Matthew Sherman¹, Payam Noroozi Farhad², Katherine Pak³, Iago Pinal-Fernandez³, Kakali Sarkar², Megan Neely⁴, Ira Targoff⁵, Frederick Miller⁶, Andrew Mammen⁷ and Lisa Rider⁸, ¹NIAMS/NIH, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, ⁵Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶NIH, NIEHS, Chapel Hill, NC, ⁷NIH, Bethesda, MD, ⁸NIEHS, NIH, Bethesda, MD
Background/Purpose: Myositis-associated autoantibodies (MAAs), such as anti-Ro52 autoantibodies (Abs), have been found to be associated with interstitial lung disease (ILD) and worse prognosis in the…
Abstract Number: 2128 • ACR Convergence 2023
Higher Vitamin D Levels Before Methotrexate Start Are Associated with Lower Subsequent Mortality in Rheumatoid Arthritis
Shahdi Malakooti¹, Hinnah Siddiqui², Brigid Wilson², Taissa Bej², Megan O'Mara², Nora Singer³, Grace McComsey⁴, Lenche Kostadinova⁵, Maya Mattar⁶, David Zidar⁵ and Donald Anthony⁷, ¹Case Western Reserve University, Cleveland, OH, ²Louis Stokes Cleveland VA Medical Center, Cleveland, OH, ³The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁴University Hospitals Health System at Case Western Reserve University, Cleveland, OH, ⁵Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, OH, ⁶Louis Stokes VA Medical Center, Cleveland, OH, ⁷Case Western Reserve University, Cleveland VA Medical Center, The MetroHealth System, Cleveland, OH
Background/Purpose: Vitamin D is an immune-modulating hormone. Low Vitamin D levels have been associated with development of autoimmune disease and higher disease activity in early…
Abstract Number: 027 • 2023 Pediatric Rheumatology Symposium
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Jessica Perfetto¹, Laura Lewandowski², Dawn Wahezi¹, Christiaan Scott³ and Angela Migowa⁴, ¹Children's Hospital at Montefiore, New York, NY, ²NIAMS, NIH, Bethesda, MD, ³Red Cross War Memorial Children's Hospital, ⁴Aga Khan University, Nairobi, Kenya
Background/Purpose: There is a paucity of data on pediatric rheumatic disease (PRD) in low and middle-income countries (LMIC), creating a false perception of low prevalence…
Abstract Number: 0539 • ACR Convergence 2022
Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use
Anna Broder¹, Wenzhu B. Mowrey², Kazuki Yoshida³ and Karen Costenbader³, ¹Hackensack University Medical Center, Hackensack, NJ, ²Albert Einstein College of Medicine, Bronx, NY, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…
Abstract Number: 1535 • ACR Convergence 2022
Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis
Jessica Fairley¹, Laura Ross², Alannah Quinlivan³, Dylan Hansen⁴, Elizabeth Paratz⁵, Wendy Stevens⁴, Peter M Kistler⁶, Andre La Gerche⁷ and Mandana Nikpour⁸, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ³St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Australia, ⁵The Baker Institute; St Vincent's Hospital Melbourne, Melbourne, Australia, ⁶The Baker Heart and Diabetes Institute; The University of Melbourne; Monash University, Melbourne, Australia, ⁷The Baker Heart and Diabetes Institute; The University of Melbourne, Melbourne, Australia, ⁸The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) Heart Involvement (SHI) is an under recognised complication of SSc and may manifest as arrhythmias or sudden cardiac death(SCD). The incidence of…
Abstract Number: 0675 • ACR Convergence 2022
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Hannah Langenfeld², Rodrigo Cartin-Ceba¹, Ulrich Specks¹, Cynthia Crowson³ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN
Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].